Home / Business and Economy / AI Drug Discovery Firm Seeks $2B+ Funding
AI Drug Discovery Firm Seeks $2B+ Funding
9 May
Summary
- Isomorphic Labs is in talks to secure over $2 billion.
- The AI-powered drug discovery company is an Alphabet subsidiary.
- Thrive Capital previously led its initial funding round.
Isomorphic Labs, an innovative AI-powered drug discovery company operating under Alphabet Inc.'s Google DeepMind umbrella, is reportedly in advanced negotiations to secure substantial new funding.
Sources familiar with the matter indicate the company aims to raise more than $2 billion. This potential funding round marks a significant step for Isomorphic Labs as it seeks to accelerate its mission of transforming drug discovery through artificial intelligence.
Notably, Thrive Capital, the venture firm that previously led Isomorphic Labs' first funding initiative, is reported to be a key participant in these ongoing discussions. The substantial capital infusion highlights the increasing confidence in AI's role within the pharmaceutical sector.
